Please login to the form below
lasmiditan
This page shows the latest lasmiditan news and features for those working in and with pharma, biotech and healthcare.
Biohaven gets FDA approval for migraine drug Nurtec ODT
Once launched it will also have to compete with Eli Lily’s new acute migraine therapy Reyvow (lasmiditan), a first-in-class 5H-T.
Latest news
-
Lilly launches migraine med Reyvow at $640 per eight-pill pack
Although Reyvow (lasmiditan) was approved by the US Food and Drug Administration last October for the treatment of acute migraine, the DEA then had to review the drug as it affects
-
Allergan gets FDA nod for first oral CGRP drug for migraine
Ubrelvy’s closest CGRP rival is Biohaven’s late-stage candidate rimegepant, which could join it on the market next year, and it also faces competition from Lilly’s Reyvow (lasmiditan),
-
Lilly set to head to regulators with CGRP migraine drug
Lilly recently added to its galcanezumab programme in migraine by buying CoLucid and its lead drug lasmiditan, an oral serotonin 5-HT 1F agonist that is due to be filed for
-
Lilly to buy migraine drug developer CoLucid for $960m
Deal revolves around lasmiditan, which the firm out-licensed in 2005. Eli Lilly has agreed a $960m deal to buy CoLucid, claiming rights to a migraine therapy that works in a ... Lasmiditan's different mechanism means it could become the first drug that
-
Migraine drugs' headache
CoLucid Pharmaceuticals is developing lasmiditan, which specifically agonises the serotonin 1F receptor.
Migraine drugs' headache
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2017
1, 000. CoLucid. Lilly. Company acquisition. Lasmiditan for the acute treatment of migraine.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- ASH 2022: bad blood but big advances
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Eli Lilly announces $450m investment in US manufacturing site
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- GSK to submit drug application for new antibiotic to US FDA
- EU outlines measures to mitigate antibiotic shortage across Europe
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
